These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34596879)

  • 1. The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden.
    Jendle J; Buompensiere MI; Holm AL; de Portu S; Malkin SJP; Cohen O
    Diabetes Ther; 2021 Nov; 12(11):2977-2991. PubMed ID: 34596879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes.
    Jendle J; Pöhlmann J; de Portu S; Smith-Palmer J; Roze S
    Diabetes Technol Ther; 2019 Mar; 21(3):110-118. PubMed ID: 30785311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Effectiveness Analysis of an Advanced Hybrid Closed-Loop Insulin Delivery System in People with Type 1 Diabetes in Greece.
    Lambadiari V; Ozdemir Saltik AZ; de Portu S; Buompensiere MI; Kountouri A; Korakas E; Sharland H; Cohen O
    Diabetes Technol Ther; 2022 May; 24(5):316-323. PubMed ID: 34962140
    [No Abstract]   [Full Text] [Related]  

  • 4. The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System Compared to Standard Management of Type 1 Diabetes in a Singapore Setting.
    Gardner D; Lakkad M; Qiu Z; Inoue Y; Rama Chandran S; Wherry K
    Diabetes Technol Ther; 2024 May; 26(5):324-334. PubMed ID: 38215206
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-Effectiveness of Hybrid Closed Loop Insulin Pumps Versus Multiple Daily Injections Plus Intermittently Scanned Glucose Monitoring in People With Type 1 Diabetes in The Netherlands.
    Serné EH; Roze S; Buompensiere MI; Valentine WJ; De Portu S; de Valk HW
    Adv Ther; 2022 Apr; 39(4):1844-1856. PubMed ID: 35226346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A European Cost-Utility Analysis of the MiniMed™ 780G Advanced Hybrid Closed-Loop System Versus Intermittently Scanned Continuous Glucose Monitoring with Multiple Daily Insulin Injections in People Living with Type 1 Diabetes.
    Jendle J; Buompensiere MI; Ozdemir Saltik AZ; de Portu S; Smith-Palmer J; Pollock RF; Cohen O
    Diabetes Technol Ther; 2023 Dec; 25(12):864-876. PubMed ID: 37801658
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of a novel hybrid closed-loop system compared with continuous subcutaneous insulin infusion in people with type 1 diabetes in the UK.
    Roze S; Buompensiere MI; Ozdemir Z; de Portu S; Cohen O
    J Med Econ; 2021; 24(1):883-890. PubMed ID: 34098834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective.
    Jendle J; Ericsson Å; Ekman B; Sjöberg S; Gundgaard J; da Rocha Fernandes J; Mårdby AC; Hunt B; Malkin SJP; Thunander M
    J Med Econ; 2020 Nov; 23(11):1311-1320. PubMed ID: 32746676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness Analysis of Sensor-Augmented Insulin Pump Therapy with Automated Insulin Suspension Versus Standard Insulin Pump Therapy in Patients with Type 1 Diabetes in Sweden.
    Jendle J; Smith-Palmer J; Delbaere A; de Portu S; Papo N; Valentine W; Roze S
    Diabetes Ther; 2017 Oct; 8(5):1015-1030. PubMed ID: 28871565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness of Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Patients with Poorly Controlled Type 2 Diabetes in Finland.
    Roze S; Smith-Palmer J; Delbaere A; Bjornstrom K; de Portu S; Valentine W; Honkasalo M
    Diabetes Ther; 2019 Apr; 10(2):563-574. PubMed ID: 30730036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the Netherlands.
    Roze S; Duteil E; Smith-Palmer J; de Portu S; Valentine W; de Brouwer BF; Reznik Y; de Valk HW
    J Med Econ; 2016 Aug; 19(8):742-9. PubMed ID: 26985982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal.
    Malkin SJP; Carvalho D; Costa C; Conde V; Hunt B
    Diabetol Metab Syndr; 2022 Feb; 14(1):32. PubMed ID: 35164855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycemic outcomes of Advanced Hybrid Closed Loop system in children and adolescents with Type 1 Diabetes, previously treated with Multiple Daily Injections (MiniMed 780G system in T1D individuals, previously treated with MDI).
    Petrovski G; Al Khalaf F; Campbell J; Day E; Almajaly D; Hussain K; Pasha M; Umer F; Hamdan M; Khalifa A
    BMC Endocr Disord; 2022 Mar; 22(1):80. PubMed ID: 35351095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness Analysis.
    Jendle J; Ericsson Å; Gundgaard J; Møller JB; Valentine WJ; Hunt B
    Diabetes Ther; 2021 Jan; 12(1):373-388. PubMed ID: 33306169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transitioning of People With Type 1 Diabetes From Multiple Daily Injections and Self-Monitoring of Blood Glucose Directly to MiniMed 780G Advanced Hybrid Closed-Loop System: A Two-Center, Randomized, Controlled Study.
    Matejko B; Juza A; Kieć-Wilk B; Cyranka K; Krzyżowska S; Chen X; Cohen O; Da Silva J; Malecki MT; Klupa T
    Diabetes Care; 2022 Nov; 45(11):2628-2635. PubMed ID: 35972259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
    Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC
    J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised controlled trial of Advanced Hybrid Closed Loop in an Adult Population with Type 1 Diabetes (ADAPT): study protocol and rationale.
    de Portu S; Vorrink L; Re R; Shin J; Castaneda J; Habteab A; Cohen O
    BMJ Open; 2022 Feb; 12(2):e050635. PubMed ID: 35110310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of Selected Psychological Parameters and Quality of Life of Patients With Type 1 Diabetes Mellitus Undergoing Transition From Multiple Daily Injections and Self-Monitoring of Blood Glucose Directly to the MiniMed 780G Advanced Hybrid Closed-Loop System: Post hoc Analysis of a Randomized Control Study.
    Cyranka K; Matejko B; Juza A; Kieć-Wilk B; Krzyżowska S; Cohen O; Da Silva J; Lushchyk M; Malecki MT; Klupa T
    JMIR Form Res; 2023 Jan; 7():e43535. PubMed ID: 36692945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
    Ericsson Å; Pollock RF; Hunt B; Valentine WJ
    J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-economic analysis of real-time continuous glucose monitoring in people with Type 1 diabetes.
    Roze S; Saunders R; Brandt AS; de Portu S; Papo NL; Jendle J
    Diabet Med; 2015 May; 32(5):618-26. PubMed ID: 25483869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.